Aardvark Therapeutics Faces Class Action Over IPO Disclosures
A law firm alleges AARD's IPO docs were flawed and statements about drug ARD-101 were misleading. Here's what shareholders need to know.
If you bought shares of Aardvark Therapeutics (NASDAQ: AARD) and watched your investment shrink, a law firm wants to hear from you. Bronstein, Gewirtz and Grossman, LLC has filed a class action lawsuit against the biotech company and certain of its officers, claiming they misled investors from the very start.
The lawsuit zeroes in on two main problems. First, it alleges that the documents Aardvark used for its initial public offering — the paperwork that's supposed to give investors a clear-eyed view of the company before they hand over their money — were negligently put together. Second, it claims that statements the company made about the safety and future prospects of its lead drug candidate, ARD-101, were false and misleading. In plain terms: investors may have been sold a rosier picture than reality warranted.
Read more MicroCloud Hologram Buys 140,268 MSTR Shares via Structured Notes →
The class period covers anyone who picked up Aardvark securities between February 13, 2025, and May 14, 2026. If that sounds like you and your portfolio took a hit, you have a specific window to act. The deadline to ask the court to be appointed as lead plaintiff — essentially the person who steers the lawsuit on behalf of all affected shareholders — is October 13, 2026. Being lead plaintiff isn't required to participate or potentially recover losses, but it does give you more say in how the case unfolds.
Class action securities lawsuits like this one are fairly common in biotech, where drug trial outcomes and regulatory hurdles can send stock prices swinging dramatically. The key legal question here will be whether Aardvark and its officers knew — or should have known — that their disclosures were deficient. That's a high bar to clear in court, but if proven, it can result in meaningful financial recovery for shareholders who were burned. Continue reading at ACCESS Newswire.
